| 000 | 01780 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517091108.0 | ||
| 264 | 0 | _c20170505 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1365-2141 | ||
| 024 | 7 |
_a10.1111/bjh.14022 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEtienne, Gabriel | |
| 245 | 0 | 0 |
_aImpact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _cJul 2016 |
||
| 300 |
_a71-80 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Observational Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFrance _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRemission Induction _xmethods |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aHuguet, Francoise | |
| 700 | 1 | _aGuerci-Bresler, Agnès | |
| 700 | 1 | _aNicolini, Franck E | |
| 700 | 1 | _aMaloisel, Frédéric | |
| 700 | 1 | _aCoiteux, Valérie | |
| 700 | 1 | _aDauriac, Charles | |
| 700 | 1 | _aCarpentier, Nathalie | |
| 700 | 1 | _aBourdeix, Isabelle | |
| 700 | 1 | _aTulliez, Michel | |
| 700 | 1 | _aCony-Makhoul, Pascale | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 174 _gno. 1 _gp. 71-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjh.14022 _zAvailable from publisher's website |
| 999 |
_c25908638 _d25908638 |
||